AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02514382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given IV
Study NCT04047004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
Study NCT00663481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoFactor
Study NCT00663481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT03110874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one-way education
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
Study NCT03110874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two-way education
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
Study NCT00474968 — intervention group
Intervention type: DEVICE
Intervention: e2 Cell Collector [SoftPAP(R)]
Description: Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]
Study NCT00474968 — intervention group
Intervention type: DEVICE
Intervention: Spatula/Brush
Description: Cervical cells collected using a combination of a cervical spatula and an endocervical brush
Study NCT01111292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: Given PO
Study NCT01111292 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01035307 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT04047004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
Study NCT00307099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
Study NCT00307099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic therapy
Description: Standard intravenous antibiotic therapy for a minimum of 8 days.
Study NCT01035307 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT01035307 — intervention group
Intervention type: GENETIC
Intervention: proteomic profiling
Study NCT01035307 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT00899847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cells (auto-PBSC) transplantation
Description: Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective
Study NCT02615301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor-made salmon with high levels of vitamin D3 and low K1
Description: The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
Study NCT02615301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement with vitamin D and Calcium
Description: The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
Study NCT02226068 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine A (CsA)
Description: 3 mg/kg/day for 4 month
Study NCT02226068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extracorporeal photopheresis (ECP)
Description: Administered two consecutive days twice a month for 4 month
Study NCT00899847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Description: Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection.
Study NCT00376493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole and doxycycline
Description: use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
Study NCT00376493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metronidazole and doxycycline
Description: use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
Study NCT01521715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
Study NCT03986801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical interview
Description: pharmaceutical interview at the end of hospitalization
Study NCT00705003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
Description: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
Study NCT00705003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCI-024 (Buspirone)
Description: Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
Study NCT00705003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo comparator once a day at bedtime for 6 weeks.
Study NCT03107091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin acetate continuous infusion
Description: Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
Study NCT00482001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Study NCT01653951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led care management or peer-led self management
Study NCT03011476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks
Study NCT03011476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks
Study NCT04633564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab as MYL-1402O
Description: Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
Study NCT04633564 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab as Avastin
Description: Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
Study NCT00909753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Ursodiol Tablets, 500 mg
Study NCT00909753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte™
Description: Urso Forte™ Tablets, 500 mg
Study NCT06558734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Preperation
Description: After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.
Study NCT06558734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cementation
Description: Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
Study NCT00841698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine HCl
Description: 40 mg Film-Coated Tablet
Study NCT00841698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil®
Description: 40 mg Film-Coated Tablet
Study NCT04451746 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combined Oral Contraceptive
Description: The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
Study NCT00482001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (cornstarch)
Study NCT01788800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 9 sessions of CBT including psychoeducation and interoceptive exposure
Study NCT01788800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 9 sessions of CBT including psychoeducation and interoceptive exposure
Study NCT00070148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Megace by mouth for 12 weeks
Study NCT00070148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone 20 mg
Description: 20 mg/day for 3 months (12 weeks)
Study NCT03969628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICCMS
Description: Risk caries assessment will consider ICCMS criteria
Study NCT01908556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT01744587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin Gallate (EGCG)
Description: EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
Study NCT01744587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo qd (2# bid) for 3 years
Study NCT02030223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: ultrasound guided transversus abdominis plane block
Study NCT02030223 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominis plane block
Description: ultrasound guided transversus abdominis plane block
Study NCT03199963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-OH tamoxifen
Description: 4-Hydroxytamoxifen (afimoxifene) gel
Study NCT03199963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
Study NCT03260153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deproteinised Calf Blood Serum Injection
Study NCT03260153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride)
Study NCT01415986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temoporfin
Description: A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
Study NCT01415986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)
Description: Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
Study NCT03910231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Oral Tablet
Description: Tolvaptan, to block V2R
Study NCT03910231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolvaptan Oral Tablet
Description: Tolvaptan, to block V2R
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
Study NCT03133715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic repair
Description: surgical repair of ventral hernia using laparoscopic repair
Study NCT03133715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted repair
Description: surgical repair of ventral hernia using robot-assisted repair
Study NCT03896425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
Study NCT03896425 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
Study NCT02643979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketofol
Description: 50mg of Ketamine mixed with 100mg of Propofol
Study NCT02643979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 100mg of Propofol
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: 10 mg PO Q12 hours for seven days
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
Study NCT00899847 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
Study NCT00899847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Description: ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 250mg
Description: MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
Study NCT00899847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
Study NCT00385229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction of labor
Description: Misoprostol, Dinoprostone, amniotomy, Oxytocin
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone
Description: 10 mg PO Q12 hours for seven days
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV iron placebo
Description: 100 mL normal saline
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron placebo
Description: 100 mL normal saline
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxandrolone placebo
Description: similar color and size sugar pill
Study NCT02047552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrolone placebo
Description: similar color and size sugar pill
Study NCT05937711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG
Description: PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)
Study NCT05937711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 30 MG
Description: Duloxetine 30 mg p.o 1X1 (daily)
Study NCT01267955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05937711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: Duloxetine 30 mg p.o 1X1 (daily)
Study NCT00588679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Description: All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
Study NCT02259231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (2.5 mg/capsule)
Description: Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label